Paola Lucia P.
- Country
- Italy
- Department
- Oncology
Research Overview
- Evaluation of Ribociclib Combined with Endocrine Therapy in Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Phase III Randomized Trial
- Phase III Randomized Double-Blind Study of Alpelisib and Fulvestrant in HR-Positive, HER2-Negative Advanced Breast Cancer with PIK3CA Mutation
- Efficacy and Safety of Palbociclib and Fulvestrant in HR+/HER2- Advanced Breast Cancer Post-CDK4/6 Inhibitor Therapy: A Phase II Multicenter Study
Data & Insights
Has run more than one trial at 33 of 225 partner sites.
Specializations
Breast Cancer Therapeutics
This investigator specializes in treating hormone receptor-positive (HR+) and HER2-negative breast cancer, with particular focus on advanced and early-stage disease management.
- Advanced Breast Cancer Treatment
- Early-stage Breast Cancer Interventions
- Metastatic Disease Management
Their research encompasses both locally advanced and metastatic breast cancer scenarios.
Endocrine Therapy Innovation
The investigator focuses on developing enhanced endocrine therapy approaches, particularly exploring combinations with targeted therapeutics.
- Novel Endocrine Treatment Strategies
- Combination Therapy Development
- Treatment Resistance Solutions
Their work includes evaluation of various endocrine therapy combinations for optimal treatment outcomes.
Targeted Therapeutic Development
Research interests include the investigation of CDK4/6 inhibitors and novel therapeutic agents in breast cancer treatment.
- Innovative Drug Development
- Treatment Sequencing Strategies
- Biomarker-Driven Therapies
The focus extends to developing personalized treatment approaches based on molecular markers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.